Table 3 Risk factors for hemoptysis
From: Safety of bronchoscopy in patients with malignant hematologic disorders
Characteristic | Patients with hemoptysis (n = 35) | Patients without hemoptysis (n = 281) | p value of univariate analysis | p value in multivariate analysis | Hazard ratio (95% CI) |
|---|---|---|---|---|---|
Age ≤ 70 years | 3 | 36 | 0.60 | ||
Sex (male/female) | 29/6 | 206/75 | 0.22 | ||
AML and MPAL | 17 | 145 | 0.74 | ||
Platelet count (≤20 × 103/μl) | 1 | 28 | 0.23 | 0.69 | |
Platelet transfusion | 17 | 117 | 0.43 | ||
Neutrophil count (≤500) | 9 | 54 | 0.36 | ||
Within 180 days from BMT except PBSCT | 4 | 57 | 0.21 | ||
Inhalation of oxygen (≥5 L/min) | 0 | 6 | 1.00 | ||
Bronchial wash | 15 | 164 | 0.26 | ||
BAL | 10 | 79 | 0.59 | ||
TBLB | 28 | 93 | 0.00 | 0.00 | 10.40 (4.18–25.90) |
Use of midazolam | 22 | 213 | 0.10 | 0.01 | 0.31 (0.14–0.73) |
Use of pethidine | 32 | 259 | 0.75 | ||
Use of atropine sulfate | 30 | 231 | 0.61 |